TOKYO -- Fujifilm Holdings will supply an active ingredient for late-stage testing of a coronavirus vaccine being developed by U.S.-based Novavax, the Japanese company said Friday.
Biotechnology
Fujifilm to supply Novavax with key part of COVID vaccine
Japanese group ties up with US biotech company for late-stage trial
A Novavax COVID-19 candidate vaccine is administered to patients in a Phase 1 clinical trial in this image from Australian Broadcasting Corp. (Photo courtesy of Novavax)
Read Next
Latest on Biotechnology
